These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 4154088)

  • 1. Delayed secondary disease in mice after early or late therapy with anti-thymocyte serum.
    Kinnamon KE; Blackwell LH; Ledney GD
    Exp Hematol; 1973; 1(4):202-14. PubMed ID: 4154088
    [No Abstract]   [Full Text] [Related]  

  • 2. Antilymphocytic antibodies and marrow transplantation. IV. Comparison of the effects of antibody fragments directed against immunoglobulin or lymphocyte antigens on acute secondary disease.
    Rodt H; Therfelder S; Eulitz M
    Exp Hematol; 1974; 2(4):195-203. PubMed ID: 4156327
    [No Abstract]   [Full Text] [Related]  

  • 3. Adaptive phenomena in bone marrow transplantation.
    Goujet-Zalc C; Ilbery PL
    Exp Hematol; 1973; 1(1):3-10. PubMed ID: 4154047
    [No Abstract]   [Full Text] [Related]  

  • 4. Bone marrow transplantation in inbred strains of mice. I. The failure of development of normal T cell function following allogeneic transplantation.
    Trier L; Rubin B
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1974 Oct; 82B(5):724-32. PubMed ID: 4139875
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts.
    Weiden PL; Doney K; Storb R; Thomas ED
    Transplant Proc; 1978 Mar; 10(1):213-6. PubMed ID: 345561
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-lymphocytic antibodies and marrow transplantation. 3. Effect of heterologous anti-brain antibodies on acute secondary disease in mice.
    Rodt H; Thierfelder S; Eulitz M
    Eur J Immunol; 1974 Jan; 4(1):15-9. PubMed ID: 4152781
    [No Abstract]   [Full Text] [Related]  

  • 7. Graft-versus-host disease.
    Gatti RA; Kersey JH; Yunis EJ; Good RA
    Prog Clin Pathol; 1973; 5():1-18. PubMed ID: 4150104
    [No Abstract]   [Full Text] [Related]  

  • 8. Of mice and men in bone marrow transplantation.
    Mathé G; Schwarzenberg L; Halle-Pannenko O; Abuaf N; Pouillart P
    Transplant Proc; 1977 Mar; 9(1):155-68. PubMed ID: 17189
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of hematopoiesis after treatment with antithymocyte serum and erythropoietin.
    Kinnamon KE; Blackwell LH; Ledney GD
    Exp Hematol; 1974; 2(4):204-11. PubMed ID: 4616844
    [No Abstract]   [Full Text] [Related]  

  • 10. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of heterologous antireceptor antibodies for specific reversal of acute homologous disease in mice].
    Nesterenko VG; Gruner Sh; Rubakova EI; Babadzhanov AS
    Biull Eksp Biol Med; 1980 Nov; 90(11):588-90. PubMed ID: 7192584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possibility of three distinct and separable components to fatal graft-vs-host reaction.
    Okunewick JP; Meredith RF; Raikow RB; Buffo MJ; Jones DL
    Exp Hematol; 1982 Mar; 10(3):277-91. PubMed ID: 7040093
    [No Abstract]   [Full Text] [Related]  

  • 14. Graft versus host disease prophylaxis today.
    Martelli MF; Aversa F
    Bone Marrow Transplant; 1991; 7 Suppl 2():112-6. PubMed ID: 1908726
    [No Abstract]   [Full Text] [Related]  

  • 15. Bone marrow transplantation. Influence of T lymphocytes on the process of differentiation and proliferation of bone marrow cells.
    Vitale B; Burek V; Plavljanić D
    Transplant Proc; 1977 Mar; 9(1):269-72. PubMed ID: 17193
    [No Abstract]   [Full Text] [Related]  

  • 16. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of graft-versus-host disease by Fab fragments derived from ALG.
    Richie ER; Gallagher MT; Trentin JJ
    Transplant Proc; 1973 Mar; 5(1):873-6. PubMed ID: 4144467
    [No Abstract]   [Full Text] [Related]  

  • 18. H-2 restriction of T cells causing lethal graft-versus-host disease across minor histocompatibility barriers in mice.
    Korngold R; Sprent J
    Transplant Proc; 1981 Mar; 13(1 Pt 2):1217-9. PubMed ID: 7022928
    [No Abstract]   [Full Text] [Related]  

  • 19. GVHD suppression by incubation of bone marrow grafts with anti-T-cell globulin: effect in the canine model and application to clinical bone marrow transplantation.
    Rodt H; Kolb HJ; Netzel B; Rieder I; Janka G; Belohradsky B; Haas RJ; Thierfelder S
    Transplant Proc; 1979 Mar; 11(1):962-6. PubMed ID: 377731
    [No Abstract]   [Full Text] [Related]  

  • 20. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation.
    Truitt RL; Johnson BD; Hanke C; Talib S; Hearst JE
    J Immunol; 1999 Nov; 163(9):5145-56. PubMed ID: 10528221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.